Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.69 |
| ▸ | PI4KA | P42356 | 2/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.69 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28680450 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL26370816 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL29408565 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL1060584 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL21999787 | 0.92 | ADORA1 (0.61) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL25966341 | 0.92 | ADORA1 (0.61) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL31139492 | 0.92 | ADORA3 (0.69) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5220374 | 0.92 | ADORA3 (0.69) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5220384 | 0.92 | ADORA3 (0.69) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL29750660 | 0.91 | ADORA1 (0.68) | ADORA1ADORA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025201529-A1 | COMPOUNDS FOR SYNTHESIZING MODIFIED SMALL ACTIVATING RNA MOLECULES, MODIFIED SMALL ACTIVATING RNA MOLECULES AND USES THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-10-02 | — | — | WO | claimed |
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-03 | — | — | US | claimed |
| US-20240368604-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2024-11-07 | — | — | US | claimed |
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2024-10-10 | — | — | US | claimed |
| US-12071623-B2 | IL-34 antisense agents and methods of using same | NOGRA PHARMA LIMITED (IE) | 2024-08-27 | — | — | US | claimed |
| EP-4341403-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | Nogra Pharma Limited (IE) | 2024-03-27 | — | — | EP | claimed |
| US-20240093197-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2024-03-21 | — | — | US | claimed |
| CN-117321206-A | IL-34 antisense agents and methods of use thereof | 诺格拉制药有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230002770-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2023-01-05 | — | — | US | claimed |
| WO-2022243299-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2022-11-24 | — | — | WO | claimed |
| CN-114729363-A | IL-34 antisense agents and methods of use thereof | 诺格拉制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| EP-4720294-A2 | MODIFIED UNC13A OLIGONUCLEOTIDES | Quralis Corporation (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4683644-A1 | FULLY MODIFIED MIR-34A AND RELATED CONJUGATES, COMPOSITIONS AND METHODS OF USE | Purdue Research Foundation (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025242321-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000076554-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-1019539-A1 | COMBINATORIAL ANTISENSE LIBRARY | Oasis Biosciences, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000020429-A1 | 3',5'-CYCLIC PHOSPHATE COMPOUNDS AND METHODS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-1999018238-A1 | COMBINATORIAL ANTISENSE LIBRARY | OASIS BIOSCIENCES, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | ADORA1 4273/4885ADORA3 4551/4885PI4KA 3876/4885 |
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CPS1, CTPS1, CTPS2 | ADORA1 4273/4885ADORA3 4551/4885PI4KA 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.